Rivastigmine Transdermal System

Product NDC: 47781-304
11-digit product format: 477810304
Labeler code: 47781
Product ID: 47781-304_dd61732f-c277-aa73-22a6-40d65fc71caa
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Rivastigmine Transdermal System
Dosage form: PATCH, EXTENDED RELEASE
Route: TRANSDERMAL
Labeler: Alvogen Inc.
Application: ANDA204403
Marketing category: ANDA
Marketing start: 2015-09-04
Marketing end: 0000-00-00
Substance: RIVASTIGMINE
Active strength: 5 mg/1
Pharmacologic classes: Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2023-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	47781-304		D	Discontinued by firm		2026-10-15
excluded package	package	47781-304	47781-304-03	D	Discontinued by firm		2026-10-15

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 20 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	47781-304-03	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	47781-304-03	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	47781-304-03	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	47781-304-03	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	47781-304-03	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	47781-304-03	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	47781-304-03	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	47781-304-03	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	47781-304-03	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	47781-304-03	`ad56d346431e…`	`cc804d4bbf1e…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	Approval date
A204403-001	RIVASTIGMINE	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	2015-09-03
A204403-002	RIVASTIGMINE	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	2015-09-03
A204403-003	RIVASTIGMINE	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	2015-08-31

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 132 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-08-31	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-08-31	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-08-31	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-08-31	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-08-31	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-09-03	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL		2015-08-31	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-08-31	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-08-31	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-08-31	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-08-31	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-08-31	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-08-31	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A204403-002	RIVASTIGMINE	9.5MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A204403-003	RIVASTIGMINE	13.3MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-08-31	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A204403-001	RIVASTIGMINE	4.6MG/24HR	FILM, EXTENDED RELEASE / TRANSDERMAL	AB	2015-09-03	`79d66fd596c7…`

Observed Orange Book normalized TE history#

Normalized TE history page 2 of 3 · 111 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2022-04-04 05:41 UTC	2022-04	A204403-002	AB	1	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	A204403-003	AB	1	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	A204403-001	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	A204403-002	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	A204403-003	AB	1	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	A204403-001	AB	1	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	A204403-002	AB	1	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	A204403-003	AB	1	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	A204403-001	AB	1	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	A204403-002	AB	1	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	A204403-003	AB	1	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A204403-001	AB	1	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A204403-002	AB	1	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	A204403-003	AB	1	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	A204403-001	AB	1	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	A204403-002	AB	1	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	A204403-003	AB	1	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	A204403-001	AB	1	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	A204403-002	AB	1	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	A204403-003	AB	1	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	A204403-001	AB	1	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	A204403-002	AB	1	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	A204403-003	AB	1	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	A204403-001	AB	1	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	A204403-002	AB	1	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	A204403-003	AB	1	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	A204403-001	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	A204403-002	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	A204403-003	AB	1	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	A204403-001	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	A204403-002	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	A204403-003	AB	1	`ea99ee380514…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	A204403-001	AB	1	`6a51e52b5d6a…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	A204403-002	AB	1	`6a51e52b5d6a…`
2024-03-16 18:09 UTC · 4 captures of this ZIP	2024-03	A204403-003	AB	1	`6a51e52b5d6a…`
2024-02-18 07:12 UTC	2024-02	A204403-001	AB	1	`1c564ffb4f44…`
2024-02-18 07:12 UTC	2024-02	A204403-002	AB	1	`1c564ffb4f44…`
2024-02-18 07:12 UTC	2024-02	A204403-003	AB	1	`1c564ffb4f44…`
2023-12-20 04:57 UTC	2023-12	A204403-001	AB	1	`ea1830bbd6c7…`
2023-12-20 04:57 UTC	2023-12	A204403-002	AB	1	`ea1830bbd6c7…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
47781-304-03	EA - Each	47781-304	bcfe3271-95e6-40a4-bd47-2f89e3f5a979	1	2015-10-02
47781-304-11	EA - Each	47781-304	ac077ab9-825b-4081-98f9-874e7c28fbe9	1	2017-11-06

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
RIVASTIGMINE	ACTIVE INGREDIENT	PKI06M3IW0	RIVASTIGMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [ALVOGEN INC.]	8
RIVASTIGMINE	ACTIVE MOIETY	PKI06M3IW0	RIVASTIGMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [ALVOGEN INC.]	8
LIGHT MINERAL OIL	INACTIVE INGREDIENT	N6K5787QVP	RIVASTIGMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [ALVOGEN INC.]	8
POLYISOBUTYLENE (1200000 MW)	INACTIVE INGREDIENT	FLT10CH37X	RIVASTIGMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [ALVOGEN INC.]	8
POLYISOBUTYLENE (400000 MW)	INACTIVE INGREDIENT	X9N69O5R5X	RIVASTIGMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [ALVOGEN INC.]	8
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	RIVASTIGMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [ALVOGEN INC.]	8

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
PKI06M3IW0	RIVASTIGMINE	123441-03-2	RIVASTIGMINE

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
47781-304-03	47781030403	30 POUCH in 1 CARTON (47781-304-03) > 1 PATCH, EXTENDED RELEASE in 1 POUCH (47781-304-11)	30 pouch	2015-09-04	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Rivastigmine Transdermal System - Alvogen Inc.	Alvogen Inc.	2024-05-01	HUMAN PRESCRIPTION DRUG LABEL	19